PRESS RELEASE published on 07/03/2024 at 08:12, 1 year 11 months ago CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities CureVac initiates strategic restructuring to focus on high-value mRNA pipeline opportunities, including workforce reduction and new GSK agreement Oncology Strategic Restructuring CureVac MRNA Pipeline GSK Agreement
PRESS RELEASE published on 07/03/2024 at 08:09, 1 year 11 months ago GSK and CureVac to Restructure Collaboration into New Licensing Agreement GSK and CureVac restructure collaboration into new licensing agreement for mRNA vaccines development, manufacturing, and commercialization globally Licensing Agreement Collaboration GSK MRNA Vaccines CureVac
BRIEF published on 06/24/2024 at 22:10, 1 year 11 months ago CureVac Announces Voting Results of General Meeting Annual General Meeting Voting Results Board Appointments CureVac MRNA
PRESS RELEASE published on 06/24/2024 at 22:05, 1 year 11 months ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of the general meeting, including board appointments and auditor reappointment. Shareholders voted in favor of all proposals Appointments Voting Results General Meeting CureVac Auditor Reappointment
BRIEF published on 05/28/2024 at 13:05, 2 years ago CureVac Announces Dosing of First Participant in Phase 2 Influenza Study GSK MRNA Technology Phase 2 Study CureVac Influenza Vaccine
PRESS RELEASE published on 05/28/2024 at 13:00, 2 years ago CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK CureVac initiates Phase 2 study in collaboration with GSK for seasonal influenza vaccine, targeting improved immune responses against influenza B strain GSK Vaccine Development Phase 2 Study CureVac Seasonal Influenza
BRIEF published on 05/23/2024 at 13:05, 2 years ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update Financial Results Business Update Q1 2024 CureVac FDA Fast Track
PRESS RELEASE published on 05/23/2024 at 13:00, 2 years ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update CureVac announces financial results for Q1 2024, reports €300.2 million cash position and updates on organizational restructuring and patent litigations Financial Results Cash Position CureVac Patent Litigation Organizational Redesign
BRIEF published on 04/24/2024 at 13:11, 2 years 1 month ago CureVac Announces 2023 Financial Results and Strategic Business Updates MRNA Technology CureVac Pharmaceutical Collaborations Oncology Vaccines Prophylactic Vaccines
BRIEF published on 04/24/2024 at 13:08, 2 years 1 month ago CureVac Begins Combined Phase 1/2 Study for Avian Influenza H5N1 Vaccine with GSK GSK CureVac Phase 1/2 Study Influenza H5N1 MRNA Vaccine
Published on 06/03/2026 at 13:00, 18 minutes ago CoTec Holdings Corp. Joint Venture, HyProMag USA, to Commence Preparatory Work for Project Execution Phase at Dallas-Fort Worth Texas Hub
Published on 06/03/2026 at 10:30, 2 hours 48 minutes ago Silver Range Partner Excalibur Metals Intersects a Broad Precious Metals Zone, Open at Depth at the Bellehelen Property
Published on 06/03/2026 at 10:00, 3 hours 18 minutes ago Eagle Plains and Xcite Define Prospective Geophysical Trends at Beaver River Uranium Project, SK
Published on 06/03/2026 at 09:01, 4 hours 17 minutes ago Apex Announces Drill Program Expansion and H2 Exploration Plans at the Rift Rare Earth Project
Published on 06/03/2026 at 12:45, 33 minutes ago Hong Kong forges new opportunities with Kazakhstan and Central Asia
Published on 06/03/2026 at 12:40, 38 minutes ago Infosys and LTA Launch AI-Driven Match and Fan Experiences at the HSBC Championships, and Beyond
Published on 06/03/2026 at 12:18, 59 minutes ago RBI on the interim status of acceptances of the voluntary public tender offer for all Addiko shares as of 3 June 2026
Published on 06/03/2026 at 12:12, 1 hour 6 minutes ago Worthington Steel Completes Acquisition of Kloeckner & Co and Announces Intention to Launch Delisting Tender Offer
Published on 06/03/2026 at 12:10, 1 hour 8 minutes ago EQS-WpÜG: Tender Offer / Target company: Klöckner & Co SE; Bidder: Worthington Steel GmbH
Published on 06/03/2026 at 12:41, 37 minutes ago Disclosure of Share Capital and Voting Rights as of Mai 31, 2026
Published on 06/03/2026 at 11:29, 1 hour 49 minutes ago 2026.06.03 Notice to holders of the Convertible Bond ISIN FR0013521085
Published on 06/03/2026 at 08:45, 4 hours 33 minutes ago Air Liquide announces milestone investment in South Korea to support SK hynix’s advanced AI memory chip project
Published on 06/02/2026 at 18:03, 19 hours 15 minutes ago Total number of voting rights and shares making up the share capital at May 31, 2026
Published on 06/02/2026 at 17:42, 19 hours 36 minutes ago Aéroports de Paris SA - Shares and voting rights as of 31 May 2026
